Medical Education Support generously provided by:
 |
 |
Genentech BioOncology |
| Millennium Pharmaceuticals, Inc. |  |
 |
 |
Exhibitors
Exhibitors Register Here
Confirmed exhibitors to date:
- Allos Therapeutics, Inc.
- Amgen
- Biogen Idec
- Cephalon Oncology
- Eisai, Inc.
- RIT Oncology LLC
Allos Therapeutics, Inc.
Allos Therapeutics, Inc. (NASDAQ: ALTH)is a biopharmaceutical company focused on developing and commercializing innovative small molecule drugs for the treatment of cancer.
Amgen
Amgen (NASDAQ:AMGN), a biotechnology pioneer, discovers, develops and delivers innovative human therapeutics. Our medicines have helped millions of patients in the fight against cancer, kidney disease, rheumatoid arthritis and other serious illnesses. With a deep and broad pipeline of potential new medicines, we continue to advance science to serve patients.
Eisai, Inc.
Eisai Inc. is a U.S. pharmaceutical subsidiary of Tokyo-based Eisai Co., Ltd., a research-based human health care (hhc) company that discovers, develops and markets products throughout the world. Eisai focuses its efforts in three therapeutic areas: neurology, gastrointestinal disorders and oncology/critical care.
RIT Oncology LLC
RIT Oncology, LLC (RadioImmunoTherapy, LLC), a wholly-owned subsidiary of Spectrum Pharmaceuticals, Inc., commercializes ZEVALIN® ([90Y]-ibritumomab tiuxetan) in the United States. ZEVALIN, a radioimmunotherapeutic (RIT), is currently approved for the treatment of patients with relapsed or refractory, low-grade or follicular B-cell non-Hodgkin’s lymphoma, including patients who have rituximab-refractory follicular NHL.
___________________________________________________________________
The 6th International Chicago Lymphoma Symposium offers a tremendous opportunity to showcase your company products, services and achievements in front of a world stage of key decision makers and industry leaders. Increase your visibility and company profile by becoming a sponsor of this exciting event.
The 6th Symposium is expected to attract over 200 leaders in the fields of medical, radiation and surgical oncology, fellows in training, oncology nurses and allied health professionals committed to preventing, controlling and eliminating lymphoma. This is an opportunity to market and showcase the broad range of products and services appropriate for Hodgkin’s and non-Hodgkin’s lymphoma.
Purpose: The Symposium will focus upon the widespread and difficult challenges of understanding and controlling Hodgkin’s and non-Hodgkin’s lymphoma. The program will feature renowned and upcoming scholars and professionals in scientific sessions.
The Symposium is undoubtedly the best opportunity for networking, sharing the latest information and discussions with the world’s leading experts in this field.
